← Leaderboards
Shruti Chaturvedi
Johns Hopkins University
$1,745,723
Attributed
$1,745,723
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,326,686 · 3
By mechanism
U54$1,580,963 · 1
K99$907,200 · 1
R00$838,523 · 1
Top collaborators
- Robert A Brodsky1 shared
- Spero R. Cataland1 shared
- Marshall Mazepa1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Robert A Brodsky$10,132,414
- Lori Chaffin Jordan$8,910,492
- Hendree E. Jones$34,132,831
- Stephanie J Murphy$4,090,469
- Patricia D. Hurn$12,295,669
Others in their field
Other Emerging Leaders on “Recovery”
- Martha Hering · Westat, Inc.$57,098,843
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Gina Montealegre · Leidos Biomedical Research, Inc.$19,781,641
- Greg Witham · Anp Technologies, Inc.$19,727,817
- Andrew S Huhn · Johns Hopkins University$16,590,830
- Laura McNay · Leidos Biomedical Research, Inc.$15,147,252
Research focus
RecoveryImmunePeptide HydrolasesRare DiseasesThrombosisThrombotic Thrombocytopenic PurpuraImpaired CognitionMorbidity - Disease RateFutureProspectiveStrokeSurvivorsHypertensionCerebral InfarctionAdultCerebrovascular DisordersLifeDisease RemissionAcuteEvaluationCohortPlasma ExchangeAnimalsAward
Grant awards (8)
Initiation of a cohort to define pathogenic Mechanisms, Precision diagnosis And Complications of Thrombotic Microangiopathies: The IMPACT Study$1,580,963
U54 · FY2025 · HL
Targeting silent cerebral infarction to improve long-term neurologic outcomes in immune thrombotic thrombocytopenic purpura (iTTP)$399,841
R00 · FY2025 · HL · contact PI
Targeting silent cerebral infarction to improve long-term neurologic outcomes in immune thrombotic thrombocytopenic purpura (iTTP)$438,682
R00 · FY2024 · HL · contact PI
ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic Purpura$213,300
K99 · FY2023 · HL · contact PI
ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic Purpura$213,300
K99 · FY2022 · HL · contact PI
ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic Purpura$54,000
K99 · FY2022 · HL · contact PI
ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic Purpura$213,300
K99 · FY2021 · HL · contact PI
ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic Purpura$213,300
K99 · FY2020 · HL · contact PI